To determine if dormant tumor cells could exploit immune escape mechanisms, we established ADR-induced tumor dormancy, followed by treatment of dormant MMC cells with IFN-γ, 3 wk after the completion of ADR treatment to provoke PD-L1 expression [15]. The gene discussed is IFNG; the disease is neoplasm.